BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 28, 2008
View Archived Issues
Astellas, CoMentis in $760M Deal for Alzheimer's Treatment
Japanese drugmaker Astellas Pharma Inc. is partnering with CoMentis Inc. to develop a compound for Alzheimer's disease under a deal potentially worth $760 million for the latter. (BioWorld Today)
Read More
FDA OKs Progenics Drug; EMA also Gives It a Nod
Read More
Japan Pharmas' Love for U.S. Biotechs Just Heating Up
Read More
Observational Trials Have Merits, but Stark Limits also Apparent
Read More
Amgen Posts Flat 1st Quarter, as Future Hinges on Denosumab
Read More
Isis Shares Slip on Need for Mipomersen Data
Read More
House Measure Reauthorizes BIO-Backed SBIR Grants
Read More
Other News To Note
Read More
Clinic Roundup
Read More